NCT07652047RecruitingPhase 1
A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
A Phase 1b Study Investigating Safety, Pharmacokinetics, and Pharmacodynamics of CX11 Tablets in Participants With Obesity or Overweight With Weight-Related Comorbidities
Source: ClinicalTrials.gov · Last updated 17 Jun 2026
Brief summary (registry, in English)
A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 11 Jun 2026
- Start date
- 11 May 2026
- Primary completion date
- Mar 2027
- Lead sponsor
- Corxel Pharmaceuticals
- Diseases
- Obesity
- NCT number
- NCT07652047
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 90
- From 11 May 2026 to the primary completion date, Mar 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diabetes or obesity due to endocrine/genetic causes.
- Personal/family history of medullary thyroid carcinoma or multiple endocrine neoplasia.
- Pregnancy, breastfeeding, recent nicotine/drug use, excessive alcohol use, or any condition/medication making participation inappropriate.
Lab values
- Recent weight-loss drugs, GLP-1-based therapy, glucose-lowering drugs, obesity surgery/device, or investigational treatment.
- Significant cardiovascular, ECG/QT, pancreatic, gallbladder, GI, liver, kidney, thyroid, psychiatric, malignant, infectious, autoimmune, or lab abnormality risks.
Who the study is looking for
- Male or female, 18-55 years.
- BMI ≥30.0 to ≤39.9 kg/m², or ≥27.0 to \<30.0 kg/m² with at least 1 weight-related comorbidity: prediabetes, hypertension, dyslipidemia, or obstructive sleep apnea.
- Prior unsuccessful diet/exercise weight-loss attempt and stable body weight within 90 days.
- Able to comply with study procedures and reproductive requirements.
Age in the registry: 18 years to 55 years · Sex: Female · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Austin | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Las Vegas | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.